The study looks at how a drug called olpasiran affects heart health in people at risk for their first major heart problem. It is compared to a placebo, which is a pill with no medicine in it, to see which works better. The focus is on people with high levels of something called lipoprotein(a), also known as Lp(a), which can increase heart disease risk. To join, you must be 50 years or older and have high Lp(a) levels, along with other heart disease risk factors. You can't join if you've had past heart problems like a heart attack or stroke. The goal is to see if olpasiran can help prevent heart issues like coronary heart disease death, heart attack, or the need for emergency artery procedures.

• Participants should be at least 50 years old and have high Lp(a) levels.
• The study checks if olpasiran can prevent first heart problems compared to a placebo.
• People with past major heart issues cannot participate.